Background: Tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) is effective against HIV acquisition when taken as prescribed. Strategies that identify and intervene with those challenged by adherence to daily medication are needed.
BACKGROUND
Tenofovir (TFV)-based oral preexposure prophylaxis (PrEP) is highly effective for HIV protection against sexual exposures when taken consistently. iPrEx, the first randomized placebo-controlled study of PrEP estimated the efficacy of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)-based PrEP to be 44%, with protection above 90% in those who had detectable drug levels in plasma samples. 1 More recent data suggest 86% reduction in HIV acquisition among men who have sex with men (MSM) in the United Kingdom randomized to immediate open-label daily TDF/FTC PrEP compared with those randomized to delayed PrEP. 2 A study of coitally dependent TDF/FTC PrEP in Quebec and France showed 86% reduction in HIV acquisition in a placebocontrolled comparison. 3 The mean number of tablets taken per week in the coitally dependent strategy was approximately 4.
Open-label PrEP cohorts have demonstrated extremely high levels of protection for MSM who had pharmacologic biomarkers consistent with sustained use of 4 or more tablets per week. 4, 5 These studies identified key populations that may have challenges adhering to PrEP at the requisite level for protection, including those disproportionately affected by HIV in the United States-young individuals and black MSM (BMSM). 6 An open-label PrEP study of youth aged 18-22 years highlighted a residual 3.3% (95% confidence interval: 0.1 to 6.5) annual HIV incidence largely attributable to nonadherence, 7 and a demonstration study for BMSM that copackaged PrEP with a client-centered care coordination model (C4) found a residual 2.9% (95% confidence interval: 0.9 to 6.8) annual incidence among BMSM who ever took PrEP, and a 7.7% (1.6 to 22.5) annual incidence among BMSM who never took PrEP. 8 Although generally safe and well tolerated, TDF/FTC PrEP is often characterized as having 3 main categories of side effects: an initial gastrointestinal "start-up" syndrome lasting 2-4 weeks and experienced by approximately 20% of users; elevations in the serum creatinine level occurring in approximately 0.2% of users and reversible on discontinuation; and loss of 1%-1.5% of bone mineral density over the first year of use, with return to baseline levels on discontinuation. 9 Although PrEP is gaining attention and acceptance as a potent HIV prevention strategy by consumers and providers alike, the cost effectiveness of PrEP for MSM is most compelling among those who are young and most consistently at risk. 10, 11 For MSM who are not recurrently at risk, postexposure prophylaxis (PEP), a limited course of 28 days of antiretroviral treatment initiated as quickly as possible after exposure, may be a lower burden, is of shorter duration, and may have less toxicity.
The PATH (PrEP and Testing/linkage to care for HIV Prevention)-PrEP study was a demonstration project at 2 community-based clinical sites in Los Angeles, which aimed to evaluate uptake, adherence, persistence to PrEP, and to assess the acceptability and impact of using drug levels to implement an escalating adherence intervention. Plasma drug levels were resulted on average 3 weeks after visits and then reported to participants within 48 hours. PATH-PrEP triaged participants to a combination HIV prevention strategy that included either PrEP or as-needed PEP. We supported adherence to daily oral PrEP using escalated adherence support guided by plasma drug concentrations over 1 year of follow-up. A vitamin D and calcium supplementation substudy will provide insight into the ability to mitigate bone mineral density loss among PrEP users. The primary outcome was the level of adherence to daily oral TDF/FTC as categorized using intraerythrocytic tenofovir diphosphate (TFV-DP) levels in dried blood spots (DBS). [12] [13] [14] 
METHODS

Study Participants
The PATH-PrEP study included self-identified MSM, MSM/W, and transgender women (TGW) age 18 years or older, HIV uninfected at study entry by rapid enzyme-linked immunosorbent assay and viral load, with adequate screening laboratory parameters, and without symptoms suggestive of primary HIV infection. The study was approved by the institutional review boards at the University of California, Los Angeles and Charles R. Drew University of Medicine and Science, and all participants provided written informed consent before screening. The Los Angeles LGBT Center (LA LGBT Center) formally relied on the UCLA IRB for regulatory oversight. The protocol was registered at clinicaltrials.gov as NCT01781806.
Study Design
Our study was a 2-arm, open-label study. Participants were triaged at study entry into either a PEP-based or a PrEPbased cohort based on self-reported risk behavior. Criteria for entering the PrEP cohort included condomless anal intercourse with 3 or more male sex partners (HIV infected or of unknown HIV serostatus) in the past 3 months, a sexually transmitted infection (STI, gonorrhea, chlamydia, or syphilis) diagnosis or PEP use in the past 12 months, or being in a sexual partnership with someone known to be HIV infected for at least 4 weeks. All other participants not meeting the above-mentioned risk criteria were offered as-needed PEP services. Participants initially triaged to the PEP-based cohort were reassessed at each follow-up visit for changes in selfreported risk behavior and were offered "escalation" to the PrEP-based cohort if above criteria were met. Eligible PrEPcohort participants who opted not to initiate TDF/FTC or discontinued TDF/FTC for safety or change in perceived risk status were followed onstudy, but offstudy medication.
PrEP-cohort participants received daily oral TDF/ FTC (Truvada; Gilead Sciences, Foster City, CA). PEPcohort participants received 2-or 3-drug PEP medication within 72 hours of a high-risk sexual exposure to an HIVinfected or HIV-status unknown partner as per Los Angeles County Division of HIV and STD Programs (DHSP) programmatic protocols.
All participants received a comprehensive HIV prevention package that included regular HIV and STI testing (with onsite treatment of STIs), risk reduction and standardized adherence counseling, and provision of condoms.
Participants were followed for 48 weeks after enrollment; participants who escalated from the PEP-based to the PrEP-based cohort were followed for 48 weeks after the initiation of PrEP-cohort participation, regardless of previous duration of follow-up in the PEP-based cohort. HIV antibody tests (OraQuick; OraSure Technologies, Inc., Bethlehem, PA) on phlebotomized blood and safety laboratory testing were performed at screening, entry, and all follow-up visits. HIV RNA testing was also performed at screening. At one of the clinical sites (LA LGBT Center), pooled RNA testing was performed on all HIV nonreactive samples throughout the study; at the other site (OASIS Clinic), RNA testing was only performed after screening with clinical suspicion of primary HIV infection.
Adherence to TDF/FTC was assessed by self-report measures, plasma TFV levels, and DBS to determine TFV-DP and FTV-TP concentrations (both by liquid chromatographytandem mass spectrometry) at all time points. 1,4 TFV plasma levels were measured at each visit and results were available within 7-21 days, and levels below the limit of quantitation (BLQ, lower limit of quantitation 10 ng/mL) triggered outreach and implementation of an escalated adherence support approach. A random sample of one-third of selected participants received MEMS caps (AARDEX Ltd., Sion, Switzerland) to measure pill bottle-opening events as a surrogate of adherence.
At each visit, participants received integrated Next-Step Counseling (iNSC, Support Level 1 15 ), a strength-based discussion focused on the identification of sexual health protection and PrEP adherence needs. Developed for and used in the iPrEx Open-Label Extension study, iNSC is based on a situated application of the Information, Motivation, Behavioral Skills model of health behavior adoption, 16 which posits that adopting a given behavior is a function of behavior-specific information, motivation, and behavioral skills. It is a basic guided approach for eliciting interactions intended to promote high levels of information, motivation, and skill relevant to sexual health and PrEP uptake using motivational interviewing and other counseling and communication strategies.
The first TFV measurement BLQ triggered escalation to Support Level 2, "targeted" integrated Next-Step Counseling (tiNSC), in which the adherence support discussion included the nondetectable drug level information and problem solving on improved dosing. Conversations were guided by an algorithm based on a participant's response to two 10-point Likert scales, one assessing the importance of PrEP and the other assessing a participant's confidence in taking PrEP medications daily.
A second (sequential or nonsequential) BLQ result triggered further escalation to Support Level 3, PrEP-STEPS. PrEP-STEPS is a 6-session intervention that is based on Lifesteps, 17, 18 an antiretroviral therapy (ART) adherence intervention. PrEP Steps uses elements of cognitive behavioral therapy (ie, motivational interviewing and problem solving) to identify and address individual barriers to PrEP adherence, as well as implementation of safer sexual behaviors. The first 4 sessions were held weekly, whereas the final 2 booster sessions were held monthly. Sessions were approximately 45 minutes in duration. All sessions involved an assessment of adherence; discussions around motivation to use PrEP and the pros and cons of use versus nonuse were conducted. If barriers to adherence were identified, comprehensive problem solving that included weighing the pros and cons of all possible solutions to the barriers was performed in a collaborative fashion. Optional modules were built into the intervention for participants who experienced mental health or substance abuse-related concerns as barriers to adherence. After completion of the escalated approach, participants returned to the basic support package (iNSC) and remained in Level 1 support unless or until another BLQ occurred. Additional BLQ results after Level 3 were considered on a case-by-case basis. Sexual behaviors were assessed at each study visit and were aggregated as number of partners for noncondomprotected receptive anal intercourse (ncRAI) and proportion of RAI events that were ncRAI.
Statistical Methods
Logistic regression was used to determine the association between each of the baseline demographic and behavioral predictors and study retention at 48 weeks, without and without adjusting for site. Logistic models were used to determine the associations between demographics and risk behaviors and intraerythrocytic TFV-DP levels dichotomized as "protective" ($700 fmol/punch), except at week 4, where the cut-off value for protective/not protective was adjusted for number of days on the TDF/FTC pre-steady state. Predictors significant with P , 0.1 in the bivariate models were added to the composite multivariable model, which was built in 1 step. Repeated measures logistic regression models were used to determine the accuracy of various self-report measures against protective TFV-DP levels.
RESULTS
Between April 2014 and July 2016, 823 individuals expressed interest in study participation. Of these, 328 were screened, and 300 MSM and 1 TGW were enrolled through 2 community-based clinics in Los Angeles ( Fig. 1 and Table 1 ). Eligible participants met inclusion criteria as noted above; individuals reporting PEP or PrEP use in the 60 days before study entry were not enrolled.
At study entry, 273 (92.4%) were assigned to the PrEPbased cohort and 23 (7.6%) were assigned to the PEP-based cohort. Six individuals originally assigned to the PEP-based cohort declined study participation (see Text, Supplemental Digital Content 1, http://links.lww.com/QAI/B79, which describes the participants assigned to the PEP-based cohort) and were considered as screen failures. During follow-up, 19 (82.6%) initially assigned to the PEP cohort "escalated" to the PrEPbased cohort based on self-reported risk behavior. Of those 19, 7 (36.8%) escalated after an episode of PEP use. For the primary analysis, we excluded the 1 TGW enrolled in the protocol, providing an analysis population of MSM exposed to PrEP of 296. Main findings were similar with the TGW participant included in the analysis. Of the 296, 13 participants had no visits after baseline, resulting in an adherence subset of 283.
Among enrolled participants, the median age was 34 (range 20-69 years). Half (50%) identified as non-Hispanic white, 33 (11%) identified as black/African American, 83 Figure 1 . Two participants met protocol-mandated stopping rules for TDF/FTC (elevated creatine phosphokinase and grade 4 psychosis); 11 participants self-assessed their risk as having declined and stopped PrEP treatment, but remained in study follow-up off TDF/FTC. Younger participants, black/African American participants, those with less education, and participants not privately insured were less likely to be retained in the cohort at week 48 (Table 1) . Including all participants assigned to the PrEP-based cohort, DBS-measured TFV-DP levels commensurate with 4 or more doses per week were found in 83.1%, 83.4%, 75.7%, 71.6%, and 65.5% of participants at weeks 4, 12, 24, 36, and 48, respectively (Fig. 2) , with lower rates of black/African American participants reaching this metric. Discounting participants known to have permanently discontinued PrEP for any reason, 4 or more doses per week were found in 84.5%, 84.9%, 77.5%, 73.6%, and 67.8% at these same time points. Adherence estimated by week 4 DBS TFV-DP level stratum and plasma TFV level stratum (from which adherence intervention escalations were triggered) is shown in Figure 3A, and B, respectively. In a multivariable model, older and nonHispanic white participants had greater odds of having TFV-DP levels commensurate with high levels of rectal protection against HIV acquisition; substance use, insurance status, education, and numbers of partners were not independently associated with increased odds of having protective TFV-DP levels ( Table 2) .
Plasma drug level results were available a mean of 21.4 days after acquisition (SD = 8.9) and tiNSC was deployed by phone within 48 hours of receipt of results at the site. Thirtyfour (12%) participants experienced a BLQ plasma TFV result during study follow-up, and 32 received the tiNSC intervention. Black and Hispanic/Latino participants accounted for more than 70% of BLQ plasma levels, accounting for 29.4% and 41.2%, respectively (P , 0.001). Of the 32 who received tiNSC, 16 (50%) had sustained improvements and 4 (12.5%) had short-term improvements (at least 1 detectable plasma level) in biomarkers of adherence after the intervention (Fig.  3C) . Four participants went on to trigger the PrEP-STEPS intervention from a second BLQ result: One participant received PrEP-STEPS, without an effect on subsequent levels, 2 were lost to follow-up, and 1 withdrew from study participation to enter substance use rehabilitation before intervention delivery.
Overall, there was a modest positive relationship between TFV plasma levels and TFV-DP levels (rho = 0.4, P , 0.001), and over the 48 weeks of follow-up, a cut-off of 70 ng/mL on the TFV plasma assay had the best operating characteristics [see Figure, Supplemental Digital Content 3, http://links.lww.com/QAI/B79, a receiver operating characteristic (ROC) curve for TFV plasma levels and protective TFV-DP levels in DBS] for association with protective TFV-DP levels at the same time point. Associations between TFV plasma levels, self-report measures, and MEMS openings were also analyzed (see Table, Supplemental Digital Content 4, http://links.lww.com/QAI/B79, bivariate generalized linear models for objective and self-report adherence predictors of rectally protective TFV-DP levels in DBS).
Percentages of participants reporting any ncRAI decreased over the first 12 weeks of study participation but then reverted to baseline levels thereafter; numbers of episodes of ncRAI per participant decreased over the first 24 FIGURE 3. A, Adherence over time as measured by intraerythrocytic TFV-DP levels in DBS samples categorized by week 4 adherence stratum. B, Adherence over time as measured by plasma TFV levels categorized by week 4 plasma-based adherence stratum. BLQ plasma levels (,10 ng/mL) triggered escalated adherence support. C, Adherence response trajectory of participants triggering escalated adherence support from plamsa TFV levels measured as BLQ (,10 ng/mL). Week 4, 8, 12, 24 , and 36 drug levels measured as TFV in plasma. Week 48 drug levels measured as FTC-TP levels in blood (measured on DBS samples, lower limit of quantitation 0.1 pmol/punch). ; the 48-week incidence rate of any STI was 53.7 per 100 person-years; individual STI incidence rates were tabulated (see Table, Supplemental Digital Content 8, http://links.lww.com/QAI/B79, STI incidence rates by study visit and specific STI). One seroconversion occurred in a participant who attended study visits per protocol through week 24 and then was lost to follow-up. Despite initially good adherence (weeks 4 and 12), his week 24 DBS specimen suggested adherence on average of fewer than 2 doses per week over the previous 4-8 weeks. He had recurrent urethral and rectal STIs 7, 9, and 10 months after study enrollment, diagnosed outside the study; he was diagnosed with HIV infection 10 months after enrollment. Pre-ART genotyping revealed the M184V mutation. The HIV incidence rate among study participants was 0.4 per 100 person-years. For comparison, the background incidence rate among MSM in Los Angeles County (uncontrolled for risk) is estimated to be 7.63 per 100 person-years (Sonali Kulkarni, MD, email communication, February 2, 2017).
Rates of adverse events were consistent with current product labeling. No discontinuations occurred for renal or bone/fracture adverse events, and there were no deaths among study participants (see Table, 
DISCUSSION
PrEP using coformulated TDF/FTC is arguably the most potent HIV prevention tool in the arsenal of effective HIV prevention interventions. Issues with differential drug pharmacokinetics in rectal tissue versus female genital tissue compartments and confounding of efficacy estimates by poor adherence has hamstrung consensus on its effectiveness across populations. 19 Anecdotal epidemiologic observations of declining new HIV infections have buoyed PrEP supporters, 20 and the ecological observation of increasing rates of bacterial STIs have galvanized PrEP detractors. 21 The optimal way to support PrEP adherence and in fact the extent to which such support is required for effectiveness remain areas of great interest and importance to the field. 15 We conducted the first trial to demonstrate the acceptability, challenges, and utility of using plasma TFV drug level monitoring with feedback to help support adherence to daily oral PrEP in a population of MSM at 2 community-based sites in Los Angeles, CA. There are concerns that efforts to support adherence to PrEP agents are likely to be resource and skill intensive and may be a prohibitive barrier to scale-up. The central tenet of the approach was that those who could be determined to be adhering at some predefined level should require little additional adherence support, and resources could be targeted to those who, despite ongoing interest in using PrEP, struggle with adherence. We observed clinically that there seem to be subsets of PrEP users who have minimal to no challenges with adherence, and therefore, deployment of adherence support efforts beyond a basic, in-clinic *Four individuals were part of the PEP-based cohort and therefore were not offered drugs; 13 individuals attended the baseline visit but missed all subsequent visits and thus never had any drug reading. None of these individuals are included in the presented data. TFV-DP concentrations in DBS measured by liquid chromatography-tandem mass spectrometry.
†The category an individual was at baseline for the repeated measures. ‡Four individuals had mislabeled or discarded samples for the week 4 visit. Subsequent readings were used to impute the week 4 drug levels. §Adjusted for site only. kMultivariable model included site, age at first visit, race/ethnicity, educational level, family income, and exchange sex in the past 30 days. NA, not applicable.
adherence and sexual health check-in would be most cost effective if targeted. Our study overlaid measurement of adherence using objective biomarkers (plasma TFV, DBS TFV-DP), with electronic drug monitoring (MEMSCaps) and self-report. We used the plasma TFV levels to apply escalating adherence support. Our results suggest that most of those challenged by adherence initially were favorably affected by a brief intervention centered around a discussion of biomarker results; however, for a minority, these benefits were not sustained over time. These results support the ongoing development of alternate prevention modalities, including injectable or slowrelease implantable options that could increase the options for choice to those who find daily pill taking to be prohibitive.
Consistent with previous demonstration projects, we found that younger PrEP users and African Americans were less likely to achieve rectally protective levels of adherence as measured by both DBS TFV-DP and plasma TFV levels, even when controlling for education, income, and other comorbidities. 5 Other work (HPTN 073) documents the structural, social, and political barriers to PrEP uptake and use among BMSM in the United States and the promise for intervention approaches that are navigational, peer, or nearpeer delivered and focused on comprehensive wrap-around services. 8 Identifying and intervening on barriers to uptake, retention, adherence, and persistence to PrEP among those most affected by the epidemic will be critical to PrEP use translating into public health and epidemic impact.
Also consistent with other work, HIV seroconversions were rare and associated with PrEP nonuse. 4, 5 The seroconversion with the M184V (3TC and FTC resistance associated) virus again reminds the clinician of the possibility of transmitted viral resistance and the hazards of restarting TDF/FTC PrEP after hiatus during which occult seroconversion might have occurred; the participant who seroconverted during this study was able to be suppressed on a well-tolerated first-line ART regimen without complication.
Interestingly, stimulant substance use was not associated with study retention or adherence. Previous data have identified clear associations between stimulant drug use and subsequent HIV seroconversion and that a substantial proportion of HIV infections among MSM are attributable to stimulants (methamphetamine in particular). [22] [23] [24] Our results in which drug levels were independent of alcohol or drug use are promising in that TDF/FTC PrEP may be highly impactful on HIV incidence at the population level if targeted to those using stimulants; in fact, a recent analysis even suggested improved adherence among some stimulant users. 25 Although we saw high rates of bacterial STIs in study participants, despite declines in proportions of self-reported ncRAI, we are cautious in both interpretation and attribution of these findings. STI rates have been increasing among MSM long before the advent of PrEP, 26, 27 and never before have highly sexually active otherwise healthy MSM been engaged in longitudinal symptomatic STI screening as frequently as every 3 months. We interpret the high rates of STIs in this study as a unique opportunity to interrupt the transmission cycle at an early time point after acquisition, thereby reducing numbers of exposed partners and secondary infections.
Although the protocol was open to TGW and marketing materials were developed with transgender community consultation to improve trans-competency of staff and instruments, we only enrolled 1 TGW. Data from designated PrEP studies designed for, and with comprehensive input from transgender individuals, are critically needed and are underway.
Should point-of-care drug level assays become a clinical reality (such are under investigation), these could be used as an important triage criterion for identifying those who might be challenged by daily oral adherence either for additional adherence interventions or alternative prevention strategies that do not require daily oral dosing.
These data expand the current understanding of the need for adherence support in PrEP clinical programs, and advance the understanding of which consumers may struggle with daily oral adherence, and support further study of biomarker-based adherence support.
